Clinical trialNCT07209267Not, yet, recruitingPhase 2Interventional

Baricitinib Curative Repression of HIV-1

SponsorEmory UniversityEnrollment35HIVHIV Infection

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This study is being done to test whether a drug called baricitinib, which blocks specific causes of inflammation, affects HIV-1 viral rebound and viral load levels after HIV treatment is discontinued. Researchers will test the effects of continuing baricitinib in people with HIV before and after discontinuing their antiretroviral therapy. This drug is approved by the Food and Drug Administration (FDA) for other diseases; it is not approved for the treatment of HIV-1. The study team will also investigate any side effects associated with the drug.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Andrew H Miller, MD
Emory University
Principal Investigator
clinicaltrials.gov ↗
Christina Gavegnano, PhD
Emory University
Principal Investigator
clinicaltrials.gov ↗
Vincent Marconi, MD
Emory University
Principal Investigator
clinicaltrials.gov ↗
William Tyor, MD
Emory University
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Dr. Gavegnano'S Laboratory
Atlanta, Georgia, United States
Grady Infectious Diseases Clinic (ponce Center)
Atlanta, Georgia, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Antiretroviral TherapyBaricitinib →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 Oct 2026
Primary completion: 31 Jan 2028
Completion: 31 Jan 2028
Last update posted: 17 Aug 2026
Registered enrollment: 35
Registry id: NCT07209267

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.